Please find the attached announcement for dissemination at the corporate announcement section of the BSE.
TECHNVISN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Technvision Ventures has forwarded a press release for BSE dissemination about its affiliate Solix Technologies signing an MoU with Symbiosis Center for Entrepreneurship & Innovation and Symbiosis Medical College for Women. The partnership will set up a Center of Excellence (CoE) focused on new drug development and drug repurposing, using AI-driven in-silico modeling combined with clinical and biomedical research. Initial focus areas are Alzheimer's disease and Priority Antimicrobial Resistant (PAMR) pathogens. The MoU was formalized during TAL HealthFest 2026. The CoE will also support IP generation, industry collaboration, CRO services, and training of UG/PG/PhD scholars in translational drug development.
This is a positive strategic development that showcases Solix Technologies (an affiliate of the listed company) moving into AI-powered pharma and healthcare, a high-growth area. It could boost investor sentiment around Technvision Ventures' innovation portfolio, though near-term financial impact is limited as this is an MoU-stage collaboration with no deal values or revenue projections disclosed.